Their findings suggest that anti-PD-L1 affibody-based immuno-PET imaging is a promising tool for glioblastoma patient stratification and could aid in the optimization of PD-1/PD-L1 checkpoint blockade therapy. The gene discussed is CD274; the disease is glioblastoma.